Monash IVF Group (ASX:MVF): FY26 Earnings, Fertility Cycles and Market Share

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Monash IVF Group (ASX:MVF): FY26 Earnings, Fertility Cycles and Market Share

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Monash IVF Group (ASX:MVF) reported FY26 Revenue of AUD 269.5 million.
Underlying FY26 NPAT was AUD 16.1 million.
Underlying EBITDA fell to AUD 53.4 million during FY26.
Monash IVF shares eased 0.33% to AUD 0.768 on 12 November 2026.

Monash IVF Group Limited (ASX:MVF) provides fertility treatment, reproductive healthcare and related diagnostic services through clinics and laboratories in Australia and international markets. Its shares stood at AUD 0.768 on 12 November 2026, a decline of 0.33% during the session. The company’s FY26 financial disclosures outlined lower earnings, a softer Australian assisted reproductive treatment market and changes in patient volumes and market share, while management continued pursuing operational and cost initiatives.

Fertility Services and Geographic Operations

Monash IVF Group (ASX:MVF) delivers assisted reproductive technology, including in vitro fertilisation, alongside fertility specialist services and ultrasound activities. Its Australian Business forms the main operating base, complemented by international services. Clinical activity depends on patient demand, treatment choices, specialist availability and the timing of stimulated cycles, rather than simply on the number of clinic locations.

The company’s February interim release reported 5,163 Australian stimulated cycles in the first half of FY26 and a decrease of 11.7% from the corresponding period. International stimulated cycles rose 6.9% over that period. These figures describe the first half, not the full-year cycle count, and the domestic and international trends should therefore be distinguished.

FY26 Trading and Operational Developments

In a June 2026 trading update, Monash IVF Group (ASX:MVF) identified softer Australian assisted reproductive treatment activity as a Factor affecting earnings. The company cited national stimulated cycles falling 4.7% over a rolling three-month period to April compared with the corresponding period. It also reported an increase in national Market Share to 20.1% on that rolling three-month basis.

The FY26 report subsequently described a rolling six-month market-share measure of 20.2%, compared with 19.0% in the first half. Different time windows explain why those percentages should not be treated as interchangeable. Management also detailed cost-efficiency work and clinical network changes, while noting that some implementation benefits were expected to contribute more in FY27 than FY26.

Full-Year Financial Results

Monash IVF Group (ASX:MVF) reported FY26 revenue of AUD 269.459 million, down 0.9% from AUD 271.917 million. Underlying EBITDA decreased 19.5% to AUD 53.419 million. Underlying net profit after tax was AUD 16.111 million, down 41.2%, and below the AUD 17–18 million range indicated in the June update.

The group reported statutory profit after tax of AUD 8.326 million, compared with AUD 25.676 million in FY25. It attributed some Earnings pressure to deferring FY26 patient price increases in eastern Australian markets, estimating an approximate AUD 6.1 million EBITDA impact. These results demonstrate the difference between Underlying Profit measures, statutory accounting results and operating Volume information.

Sector Risks and Upcoming Events

For Monash IVF Group (ASX:MVF), patient demand, fertility treatment affordability, clinician recruitment, clinic operating expenses and changes in the domestic treatment market remain relevant variables. Market-share gains may not fully offset a decline in the overall number of procedures, especially where pricing and fixed operating costs affect the relationship between activity and earnings.

Future monitoring points include stimulated-cycle trends, progress on operating efficiencies, regional market-share changes and FY27 financial reporting. The company scheduled its 2026 Annual General Meeting for 26 November in Melbourne. The meeting provides another formal opportunity for Shareholder communications, but it should not be assumed to contain a particular financial outcome.

Key Insights

Monash IVF Group (ASX:MVF) recorded lower revenue and underlying earnings in FY26 while identifying pressure on Australian treatment demand. International activity and some domestic market-share measures improved, but the group’s statutory profit also declined. Future performance assessments will depend on reported patient activity, pricing decisions, clinic costs and evidence of benefits from operational changes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.